Beyond elevating EPO plasma levels, Roxadustat could correct the degree of anemia by handling iron metabolism and particularly by decreasing hepcidin plasma levels, a response that is independent of the baseline CRP plasma levels and disease state of the CKD patient. This evidence concerns the gene EPO and chronic kidney disease.